Efficacy of sintilimab combined with albumin-bound paclitaxel and platinum-based chemotherapy in patients with stage ⅢB-Ⅳ lung squamous cell carcinoma and its impact on tumor markers
Objective To investigate the clinical efficacy of sintilimab combined with paclitaxel(albumin-binding type)and platinum-based chemotherapy for stage ⅢB-Ⅳ lung squamous cell carcinoma(LSCC)and its impact on tumor markers.Methods Retrospective analysis was conducted for clinical data of 87 patients with stage ⅢB-Ⅳ LSCC admitted to Leshan People's Hospital from June 2021 to March 2023.These patients were divided into two groups according to the different medication regimens.The patients in the control group(n=39)received paclitaxel(albumin-binding type)and platinum-based chemotherapy while those in the observation group(n=48)received sintilimab in addition.All the patients in both groups were treated for at least 12 weeks and then the clinical efficacy,tumor markers,adverse reactions and survival were compared between the two groups.Results After treatment,the observation group reported higher objective remission rate and disease control rate as compared with the control(41.67%vs 20.51%,81.25%vs 61.54%,P<0.05).Meanwhile,the observation group had lower serum concentrations of carcinoembryonic antigen,cytokeratin 19 fragment and squamous cell carcinoma antigen than the control((5.78±1.51)ng·mL-1 vs(8.45±1.87)ng·mL-1,(4.34±1.21)ng·mL-1 vs(6.02±2.02)ng·mL-1,(16.78±3.45)ng·mL-1 vs(25.48±4.31)ng·mL-1,all P<0.05).No statistical difference was found in adverse reaction rate between the two groups(P>0.05).The median progression-free survival(PFS)and overall survival(OS)in the observation group were 14.09 months and 17.59 months,respectively,which were longer than 10.82 months and 12.88 months in the control(P<0.05).Conclusion Sintilimab combined with paclitaxel(albumin-binding type)and platinum-based chemotherapy can effectively ameliorate the expression of tumor markers and has a good safety profile in patients with stage ⅢB-Ⅳ LSCC.
NETL
NSTL
万方数据
